Indication

For the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

Medicine details

Medicine name:
voretigene neparvovec (Luxturna)
SMC ID:
SMC2228
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Eye
Submission type
Ultra-orphan initial assessment
Status
Publication due date:
09 December 2019
SMC meeting date:
05 November 2019
Patient group submission deadline:
30 September 2019